New drug trial targets Tough-to-Treat stomach cancers

NCT ID NCT07143604

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called AZD0901 for people with advanced stomach or gastroesophageal junction cancer that has spread and expresses a specific protein called CLDN18.2. It is for adults whose cancer has continued to grow after at least one prior treatment. The main goal is to see if the drug can shrink tumors and how safe it is for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Chelyabinsk, 454092, Russia
Research Site
NOT_YET_RECRUITING

Krasnoyarsk, 660133, Russia
Research Site
RECRUITING

Kuzmolovskiy, 188663, Russia
Research Site
RECRUITING

Moscow, 111123, Russia
Research Site
RECRUITING

Moscow, 115478, Russia
Research Site
RECRUITING

Moscow, 115533, Russia
Research Site
RECRUITING

Moscow, 125284, Russia
Research Site
RECRUITING

Moscow, 142770, Russia
Research Site
RECRUITING

Moscow, 143423, Russia
Research Site
RECRUITING

Nizhny Novgorod, 603126, Russia
Research Site
NOT_YET_RECRUITING

Novosibirsk, 630108, Russia
Research Site
RECRUITING

Saint Petersburg, 197022, Russia
Research Site
RECRUITING

Saint Petersburg, 197758, Russia
Research Site
RECRUITING

Volgograd, Unk, Russia

Conditions

Explore the condition pages connected to this study.

GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER